Banque Cantonale Vaudoise Has $2.84 Million Stock Position in Avantor, Inc. (NYSE:AVTR)

Banque Cantonale Vaudoise grew its stake in shares of Avantor, Inc. (NYSE:AVTR) by 66.8% in the 3rd quarter, HoldingsChannel reports. The fund owned 109,777 shares of the company’s stock after purchasing an additional 43,970 shares during the quarter. Banque Cantonale Vaudoise’s holdings in Avantor were worth $2,840,000 as of its most recent filing with the Securities & Exchange Commission.

A number of other institutional investors also recently made changes to their positions in the company. SG Americas Securities LLC acquired a new stake in Avantor during the 1st quarter worth approximately $159,000. Acadian Asset Management LLC lifted its holdings in shares of Avantor by 45.8% during the first quarter. Acadian Asset Management LLC now owns 22,678 shares of the company’s stock worth $579,000 after buying an additional 7,120 shares in the last quarter. Edgestream Partners L.P. bought a new stake in shares of Avantor in the first quarter valued at about $1,242,000. UniSuper Management Pty Ltd grew its stake in shares of Avantor by 97.9% in the first quarter. UniSuper Management Pty Ltd now owns 9,500 shares of the company’s stock valued at $243,000 after acquiring an additional 4,700 shares in the last quarter. Finally, CANADA LIFE ASSURANCE Co grew its stake in shares of Avantor by 0.6% in the first quarter. CANADA LIFE ASSURANCE Co now owns 553,982 shares of the company’s stock valued at $14,168,000 after acquiring an additional 3,038 shares in the last quarter. Institutional investors own 95.08% of the company’s stock.

Analysts Set New Price Targets

A number of research firms have issued reports on AVTR. UBS Group cut their price objective on shares of Avantor from $30.00 to $29.00 and set a “buy” rating for the company in a report on Tuesday, October 8th. TD Cowen boosted their price target on Avantor from $28.00 to $31.00 and gave the company a “buy” rating in a research note on Monday, July 29th. Robert W. Baird lowered their price objective on Avantor from $27.00 to $26.00 and set an “outperform” rating on the stock in a research note on Monday, October 28th. Stifel Nicolaus upped their target price on Avantor from $27.00 to $28.00 and gave the company a “buy” rating in a research report on Monday, July 29th. Finally, Wells Fargo & Company reduced their target price on Avantor from $30.00 to $28.00 and set an “overweight” rating on the stock in a report on Monday, October 28th. Three equities research analysts have rated the stock with a hold rating and twelve have issued a buy rating to the company’s stock. According to MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and an average price target of $27.57.

Avantor Stock Performance

Shares of Avantor stock opened at $19.72 on Wednesday. The firm has a market capitalization of $13.42 billion, a P/E ratio of 42.86, a P/E/G ratio of 2.52 and a beta of 1.35. Avantor, Inc. has a fifty-two week low of $19.23 and a fifty-two week high of $28.00. The company has a debt-to-equity ratio of 0.84, a current ratio of 1.54 and a quick ratio of 1.06. The company’s 50 day moving average price is $24.27 and its two-hundred day moving average price is $23.94.

Insider Buying and Selling at Avantor

In related news, CAO Steven W. Eck sold 3,525 shares of the firm’s stock in a transaction on Thursday, September 5th. The stock was sold at an average price of $25.06, for a total transaction of $88,336.50. Following the completion of the transaction, the chief accounting officer now directly owns 29,544 shares of the company’s stock, valued at $740,372.64. This trade represents a 10.66 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink. Corporate insiders own 1.30% of the company’s stock.

Avantor Company Profile

Avantor, Inc engages in the provision of mission-critical products and services to customers in the biopharma, healthcare, education and government, advanced technologies, and applied materials industries in the Americas, Europe, Asia, the Middle East, and Africa. The company offers materials and consumables, such as purity chemicals and reagents, lab products and supplies, formulated silicone materials, customized excipients, customized single-use assemblies, process chromatography resins and columns, analytical sample prep kits, education and microbiology products, clinical trial kits, peristaltic pumps, and fluid handling tips.